Results 241 to 250 of about 10,318 (317)

GLP-1RA and the risk of non-arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population-based study. [PDF]

Diabetes Obes Metab
Tesfaye H, Paik JM, Wexler DJ, Hathaway JT, Yu EW, Freedman A, Rizzo JF, Patorno E.   +7 more
europepmc   +1 more source

Microglia Involvement into Acute and Chronic Brain Damage in Diabetic Rats: Impact of GLP-1RA and SGLT-2i [PDF]

А. В. Симаненкова, Oksana Fuks, Н. В. Тимкина, Alina Islamova, Д. А. Суфиева, О. В. Кирик, Д. Э. Коржевский, Т. Д. Власов, Т. Л. Каронова   +8 more
openalex   +1 more source

Impact of SGLT2i and GLP-1RA on liver-related events in patients with MASLD and type 2 diabetes: A network meta-analysis. [PDF]

JHEP Rep
Li L, Mao X, Lee CH, Wai Lui DT, Wan-Hin Hui R, Mak LY, Yuen MF, Cheung KS, Seto WK.   +8 more
europepmc   +1 more source

Effects of GLP‐1 Receptor Agonists on Hair Loss and Regrowth: A Systematic Review

International Journal of Dermatology, Volume 65, Issue 5, Page 1030-1032, May 2026.
Miranda K. Branyiczky, Megan S. Lowe, Eric McMullen, Jeffrey Donovan, Touraj Khosravi‐Hafshejani   +4 more
wiley   +1 more source

IL-27, a metabolic regulator secreted by astrocytes in response to GLP-1RA OHP2, modulates microglial reprogramming in Alzheimer's disease by regulating cGAS lactylation. [PDF]

J Neuroinflammation
Du Y, Wu L, Mao Y, Chen S, Gao X.
europepmc   +1 more source

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP ‐ 1RA ‐based weight‐loss therapies [PDF]

Reimar W. Thomsen, Aurélie Mailhac, Julie B. Løhde, Anton Pottegård   +3 more
openalex   +1 more source

GLP-1RA may open a new era for MASLD treatment

Clinical and Molecular Hepatology
Ye, Feng, Chengfu, Xu
openaire   +2 more sources

Gut microbiota modulation in GLP-1RA and SGLT-2i therapy: clinical implications and mechanistic insights in type 2 diabetes. [PDF]

Clin Kidney J
Kanbay M, Al-Shiab R, Shah E, Ozbek L, Guldan M, Ortiz A, Fouque D.   +6 more
europepmc   +1 more source

GLP-1RA and SGLT2i utilization in people with type 2 diabetes with atherosclerotic cardiovascular disease (ASCVD) or at high risk of ASCVD in the Gulf Region [PDF]

Waleed A. Al-Dahi, Saeed Khalaf, Dalal Alromaihi, Naji Alamuddin, Hessa M. al Kandari, Doaa K. Abdalla, Hanan Y. Alfadehla, Amin Jayyousi, Mashhood A. Siddique, Usama AlAlami, Guruprasad Subbarao, Shashikanth Chetty, Jehan Abdulla   +12 more
openalex   +1 more source

Exploring the risk of depression and suicide/self-injury in patients receiving GLP-1RAs combined with metformin versus GLP-1RA monotherapy: a real-word analysis of the FAERS database. [PDF]

Endocr Connect
Ji W, Ma Y, Fang J, Chen L.
europepmc   +1 more source